Ranitidine Hydrochloride Injection is an acid-suppressing drug, and its main effects include inhibition of basal and nocturnal gastric acid secretion in normal and ulcer patients, and gastric acid secretion induced by pentagastrin, histamine, and meals; inhibition of pepsinogen secretion; and protection against experimental gastric mucous membrane damage and acute ulcers. Clinically used for peptic ulcer bleeding, diffuse gastric mucosal lesion bleeding, anastomotic ulcer bleeding, gastric surgery to prevent re-bleeding, etc.; acute gastric mucous membrane damage and aspirin-induced acute gastric mucous membrane damage concurrently with the state of stress; prevention of stress ulcer hemorrhage under the state of stress of severe disease; general anesthesia or postoperative and debilitating coma patients to prevent acid reflux combined with aspiration pneumonia. Adverse reactions to ranitidine hydrochloride injection include nausea, vomiting, constipation, diarrhea, abdominal discomfort, pancreatitis, headache, dizziness, insomnia, somnolence, cardiac arrhythmia, leukopenia, granulocytopenia, thrombocytopenia, arthralgia, myalgia, feminization of the gynecomastia, impotence, decreased libido, sedation of the local burning or pruritisation sensation, anaphylactic reaction, alopecia and other symptoms. In addition, it is contraindicated in patients who are allergic to ranitidine hydrochloride injection and its contained ingredients, used with caution in patients with severe hepatic or renal insufficiency, avoided in patients with a history of porphyria, used with caution in pregnant women and lactating mothers, contraindicated in children under the age of 8 years, and in infants limited to necessary cases. This product is usually administered in hospitals by healthcare professionals.